Kelvyn Cullimore

Opinion: To support biopharmaceutical breakthroughs in Utah, it’s time to revisit federal merger policies
By 
Kelvyn Cullimore
Opinion: Addressing the unfair 'pill penalty' in drug pricing
By 
Kelvyn Cullimore
Opinion: A $22 billion life sciences engine vs. Washington red tape
By 
Kelvyn Cullimore
This plan to cut drug prices could result in lost jobs and fewer medicines. Here’s why
By 
Kelvyn Cullimore
Committing to #MaskUpUtah protects us, our neighbors and our economy
By 
Kelvyn Cullimore